About This Fund
AAIC Africa Healthcare Fund (AHF-1) is the debut Africa-focused venture and impact fund managed by AAIC Investment, a Japan-based investment firm specializing in cross-border investments between Japan and Africa. Established in 2017, AHF-1 was the first Japan-based fund dedicated exclusively to healthcare innovation in Africa, pioneering a new model of capital deployment that combines Japanese institutional capital with Africa-focused startup investing in healthcare and health-enabling technology.
AHF-1 provides venture and growth capital to African startups operating across the healthcare value chain, including clinical care, medical services, digital health platforms, medical devices, and health-enabling fintech applications. The fund focuses on stage-agnostic investments in companies addressing critical healthcare access, affordability, and quality challenges across sub-Saharan Africa and North Africa, with concentrated portfolio exposure in Kenya, Nigeria, Rwanda, Uganda, Egypt, Tanzania, South Africa, Ethiopia, and Ghana. AAIC Investment's dual Japan-Africa network is central to the investment model: Japanese corporate strategics in the pharmaceutical, medical device, and trading sectors participate both as LP investors and as potential commercial partners or distribution channels for portfolio companies seeking access to Asian markets.
AHF-1 formed the foundation of AAIC Investment's Africa healthcare investment platform, which has since grown to a combined size of approximately $87 million (approximately 13 billion yen) across AHF-1 and its successor fund, the AAIC Africa Innovation & Healthcare Fund (AHF No. 2). Portfolio companies from the AAIC fund family have achieved international recognition, including five companies selected as Time magazine's 100 World's Top HealthTech Companies of 2025 — a benchmark that validates the quality of AAIC's investment thesis and the commercial potential of African health technology businesses. Japanese institutional and corporate investors such as Asahi Intecc, Eisai, Ohara Pharmaceutical, and Marubeni Corporation have participated as LP investors across the AAIC fund family.